Natco Gets Defensive As Indian Regulator Threatens Criminal Action For Marketing Substandard Product
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Albumin-bound paclitaxel drug Abraxane - used in the treatment of breast cancer - has been troubling its innovator, Abraxis Bioscience, and its only Indian generic maker, Natco Pharma, alike
You may also be interested in...
India’s Dr. Reddy’s, Natco Strike Deal To Target Abraxane And Several Other Oncology Drugs
MUMBAI - Highly profitable generic drugs - mainly in the oncology segment - are the latest targets for Indian pharmaceutical companies as margins rapidly shrink on commoditized off-patent drugs in the U.S. and several other markets. With that objective, India's Dr. Reddy's Labs and Natco, a company specializing in oncology drugs have signed a deal for the development, manufacture and supply of a basket of value added generic oncology drugs
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).